Dow Up0.59% Nasdaq Up0.75%

Aeolus Pharmaceuticals Inc. (AOLS)

-Other OTC
0.40 Sep 16, 11:41AM EDT
|Pre-Market : NaN
ProfileGet Profile for:
Aeolus Pharmaceuticals Inc.
26361 Crown Valley Parkway
Suite 150
Mission Viejo, CA 92691
United States - Map
Phone: 949-481-9825
Website: http://www.aeoluspharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:4

Business Summary 

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the development of a platform of novel compounds in biodefense and oncology. The company develops a class of catalytic antioxidant compounds as medical countermeasures against biological, chemical, and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. Its lead compound, AEOL 10150, which has completed 2 Phase I clinical trials is developed against the pulmonary sub-syndrome of acute radiation syndrome, as well as for the gastrointestinal sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants, such as chlorine gas, sulfur mustard gas, phosgene gas, and nerve agents. The company is also developing AEOL 11207, AEOL 10113, and AEOL 10171 for the treatment of epilepsy and Parkinson’s disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Aeolus Pharmaceuticals Inc.

Key Executives 
 PayExercised
Mr. David C. Cavalier , 45
Chairman of The Board, Chief Financial Officer, Principal Accounting Officer and Sec.
342.00K0.00
Mr. John L. McManus , 50
Chief Exec. Officer and Pres
421.00K0.00
Mr. Christopher Stanley ,
VP of Operations
N/AN/A
Dr. Brian J. Day Ph.D., 54
Chief Scientific Officer
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders